期刊文献+

老年患者VKORC1和CYP2C9基因多态性对华法林应用的影响及分析 被引量:6

Effect of Polymorphism in VKORC1 and CYP2C9 on Warfarin Dosage in Elderly Patients
原文传递
导出
摘要 目的探求遗传因素和非遗传因素对≥60岁老年人华法林应用的影响。方法纳入≥60岁使用华法林的老年患者,收集患者血液样本并检测患者VKORCl和CYP2C9基因型,收集患者临床资料,统计分析遗传因素和非遗传因素对华法林稳定剂量的作用与影响。结果 VKORCl和CYP2C9基因型对华法林剂量有显著影响,VKORC1:1173C>T,体重、AST(谷草转氨酶)、CYP2C9*3 4个变量可以解释23.2%的华法林稳定期用量的变异。结论遗传因素在老年患者华法林作用影响巨大,VKORCl和CYP2C9基因多态性检测同样适用于老年患者的华法林个体化用药。 OBJECTIVE To explore the effect of genetic factors and non-genetic factors on warfarin dosage in patients older than 60 years. METHODS Patients older than 60 years were included. Blood samples were collected and tested for VKORC1 and CYP2C9 genotypes. And the clinical data were collected. The effects of genetic factors and non-genetic factors on stable dosage of warfarin were statistically analyzed. RESULTS VKORC1 and CYP2C9 genotypes had a significant effect on warfarin dosage. The four variables, ie, VKORC1 : 1173C 〉 T, body weight, aspartate aminotransferase (AST), and CYP2C9 * 3 could explain 23.2% of the stable warfarin dosage variation. CONCLUSION Genetic factors have significant effect on warfarin dosage in elderly patients, so genetyp- ing on VKORC1 and CYP2C9 can be applied to individualize warfarin dosage in elderly patients.
出处 《中国药学杂志》 CAS CSCD 北大核心 2012年第23期1930-1933,共4页 Chinese Pharmaceutical Journal
基金 卫生行业科研专项基金"药物使用安全与输血安全相关技术与标准"(200902008-03) 国家食品药品监督管理局药品评价中心国家科技支撑计划课题"安全用药关键技术与应用"(2006BAI14B04)
关键词 华法林 老年患者 VKORC1 CYP2C9 基因多态性 个体化用药 warfarin elderly patient VKORC1 CYP2C9 genetic polymorphism individualization medication
  • 相关文献

参考文献2

二级参考文献22

  • 1Feinberg WM,Blackshear JL,Laupacis A,et al.Prevalence,age distribution,and gender of patients with atrial fibrillation.Analysis and implication.Arch Intern Med,1995,155:469-473.
  • 2Coodacre S,Irons R.ABC of clinical electrocardio-graphy:atrial arrhythmias.Br Med J,2002,324:594-597.
  • 3Go AS,Hylek EM,Phillips KA,et al.Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention-the Anticoagulation and Risk Factors in Atrial Filbrillation (ATRIA) Study.JAMA,2001,285:2370-2375.
  • 4Rockson SG,Albers GW.Comparing the guidelines:anticoagulation therapy to optimize stroke prevention in patients with atrial filbrillation.J Am Coll Cardiol,2004,43:929-934.
  • 5Wolf PA,Abbott RD,Kannel WB,et al.Atrial fibrillation as an independent risk factor for stroke:the Framingham study.Stroke,1991,22:983-988.
  • 6Mesas CE,Veloso HH,De Paola AA.Anticoagulation for atrial fibrillation:underutilization in a Brazilian tertiary outpatient clinic.Clin Cardiol,2004,27:592-593.
  • 7York M,Agarwal A,Ezekowitz M.Physicians' attitudes and the use of oral anticoagulants:surveying the present and envisioning future.J Thromb Throm-bolysis,2003,16:33-37.
  • 8Pengo V,Legnani C,Noventa F,et al.Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding.A multicenter inception cohort study.Thromb Haemost,2001,85:418-422.
  • 9Yamaguchi T.Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation,a multicenter,prospective,randomized trial,Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group.Stroke,2000,31:817-821.
  • 10Vermaons KN,Takis CE,Geogils K,et al.The Athens stroke registry:results of a five year hospital-based study.Cerebrovasc Dis,2000,10:133-142.

共引文献7

同被引文献61

  • 1张松波,周宏灏.药物代谢性别差异及与核受体的关系[J].中国药理学通报,2007,23(3):292-294. 被引量:23
  • 2郑策,梅丹.影响华法林抗凝血作用的有关因素[J].药物不良反应杂志,2007,9(4):256-261. 被引量:102
  • 3耿强,郭丹杰.65岁以上老年患者口服华法林抗凝的安全性探讨[J].中西医结合心脑血病杂志,2009,7(7) :834-835.
  • 4Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmaeoge- netic data[J]. N Engl J Med,2009,360(8):753-764.
  • 5Wen MS,Lee M,Chen JJ,et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes[J]. Clin Pharamacol Ther, 2008,84(1): 83-89.
  • 6Ohno M, Yamamoto A, Ono A, et al. Influence of clinical and genetic factors on warfarin dose require- ments among Japanese patients [J]. Eur J Clin Pharamacol. 2009,65 ( 11 ) : 1097-1103.
  • 7Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of wafarin in first year of therapy among elderly patients with atrial fibrillation [J]. Circulation,2007,115 (21) : 2689-2696.
  • 8Yang L, Ge W, Yu F, et al. Impact of VKORC1 gene polymorphism on inter-individual and intereth- nic warfarin dosage requirement-a systematic review and meta-analysis[J]. Thromb Res,2010,125(4) : e159-e166.
  • 9Wei M,Ye F,Xie D,et al. A new algorithm to pre- dict warfarin dose from poiymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: Derivation in Han Chinese patients with non valvular fibrillation[J]. Thromb Haemost,2012,107(6) 11083-1091.
  • 10Sanderson S,Emery J, Higgins J. CYP2C9 geneva riants, drug dose, and bleeding risk in warfarin-trea ted patients:a HuGEnet systematic review and me ta-analysis[J]. Genet Med,2005,7(2):97-104.

引证文献6

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部